UK Medical Cannabis Registry: An Analysis of Clinical Outcomes of Medicinal Cannabis Therapy for Cancer Pain

Journal of Pain & Palliative Care Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: Feb. 8, 2025

Cancer pain (CP) is a prevalent condition with limited pharmacotherapeutic options. Cannabis-based medicinal products (CBMPs) have shown analgesic effects, but their efficacy in CP remains contentious. This study aims to evaluate the change patient-reported outcome measures (PROMs) and adverse events (AEs) patients treated CBMPs. A case series was conducted using prospectively collected clinical data from UK Medical Cannabis Registry. Primary outcomes were changes Brief Pain Inventory (BPI), visual analogue scale (Pain-VAS), EQ-5D-5L, Generalized Anxiety Disorder-7 (GAD-7), Patient Global Impression of Change (PGIC) Single-Item Sleep Quality Scale (SQS) questionnaires baseline 1, 3, 6 months. AEs recorded graded. p < 0.050 considered statistically significant. One hundred sixty-eight participants included. CBMPs associated improvements all pain-specific PROMs at follow-up periods (p 0.050). Improvements GAD-7, SQS, EQ-5D-5L index scores also observed Twenty-nine (17.26%) reported by five (2.98%), mostly mild-to-moderate (72.41%). Although observational design means causality cannot be established, findings support development future randomized controlled trials into management

Language: Английский

---

UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility‐Associated Chronic Pain

ACR Open Rheumatology, Journal Year: 2025, Volume and Issue: 7(3)

Published: March 1, 2025

Objective The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers–Danlos syndrome (hEDS) chronic pain following treatment cannabis‐based medicinal products (CBMPs). Methods This was a case series conducted UK Medical Cannabis Registry. primary were changes validated patient‐reported outcome measures at 1, 3, 6, 12, 18 months compared baseline: Short‐Form McGill Pain Questionnaire 2 (SF‐MPQ‐2), visual analog scale score (Pain‐VAS), Brief Inventory (BPI), five‐level EQ‐5D (EQ‐5D‐5L), Single‐Item Sleep Quality Scale (SQS), General Anxiety Disorder Seven‐Item (GAD‐7), Patient Global Impression of Change. incidence adverse events analyzed as secondary outcomes. Statistical significance defined P <0.050. Results A total 161 met inclusion criteria. Improvements observed BPI severity interference subscales, SF‐MPQ‐2, Pain‐VAS ( < 0.001). Changes also seen EQ‐5D‐5L index value, SQS, GAD‐7 50 (31.06%) reported one or more event 601 (373.29%). most frequent rating for moderate (n = 258; 160.25%), headache being common 44; 27.33%). Conclusion An association identified between HSD/hEDS improvements pain‐specific general health‐related quality life commencement CBMPs. CBMPs well tolerated months. These findings must be interpreted within context limitations design but add further weight calls randomized controlled trials.

Language: Английский

---

Illicit Cannabis Use to Self-Treat Chronic Health Conditions in the United Kingdom: Cross-Sectional Study

JMIR Public Health and Surveillance, Journal Year: 2024, Volume and Issue: 10, P. e57595 - e57595

Published: June 17, 2024

Abstract Background In 2019, it was estimated that approximately 1.4 million adults in the United Kingdom purchased illicit cannabis to self-treat chronic physical and mental health conditions. This analysis conducted following rescheduling of cannabis-based medicinal products (CBMPs) but before first specialist clinics had started treating patients. Objective The aim this study assess prevalence consumption treat a medically diagnosed condition introduction could prescribe legal CBMPs Kingdom. Methods Adults older than 18 years were invited participate cross-sectional survey through YouGov between September 22 29, 2022. A series questions asked about respondents’ medical diagnoses, use, cost purchasing per month, basic demographics. responding sample weighted generate representative adult population Modeling size based on an (18 or older) 53,369,083 according 2021 national census data. Results There 10,965 respondents questionnaire, which weighting applied. total 5700 (51.98%) indicated they affected by condition. most reported anxiety (n=1588, 14.48%). Of those enduring conditions, 364 (6.38%) Based responses, modeled 1,770,627 (95% CI 1,073,791‐2,467,001) individuals consume for conditions across multivariable logistic regression, associated with increased likelihood reporting use reasons—chronic pain, fibromyalgia, posttraumatic stress disorder, multiple sclerosis, other disorders, male sex, younger age, living London, being unemployed not working reasons, part-time ( P <.05). Conclusions highlights scale reasons potential barriers accessing legally prescribed CBMPs. is important step developing harm reduction policies transition these individuals, where appropriate, Such are particularly considering risks from harmful contaminants self-treating without clinical oversight. Moreover, emphasizes need further funding randomized controlled trials novel methodologies determine efficacy their common

Language: Английский

---

Predicting therapy dropout in chronic pain management: a machine learning approach to cannabis treatment

Frontiers in Artificial Intelligence, Journal Year: 2025, Volume and Issue: 8

Published: Feb. 20, 2025

Chronic pain affects approximately 30% of the global population, posing a significant public health challenge. Despite their widespread use, traditional pharmacological treatments, such as opioids and NSAIDs, often fail to deliver adequate, long-term relief while exposing patients risks addiction adverse side effects. Given these limitations, medical cannabis has emerged promising therapeutic alternative with both analgesic anti-inflammatory properties. However, its clinical efficacy is hindered by high interindividual variability in treatment response elevated dropout rates. A comprehensive dataset integrating genetic, clinical, information was compiled from 542 Caucasian undergoing cannabis-based for chronic pain. machine learning (ML) model developed validated predict therapy dropout. To identify most influential factors driving dropout, SHapley Additive exPlanations (SHAP) analysis performed. The random forest classifier demonstrated robust performance, achieving mean accuracy 80% maximum 86%, an AUC 0.86. SHAP revealed that final VAS scores THC dosages were predictors strongly correlated increased likelihood discontinuation. In contrast, baseline benefits, CBD dosages, CC genotype rs1049353 polymorphism CNR1 gene associated improved adherence. Our findings highlight potential ML pharmacogenetics personalize therapies, improving adherence enabling more precise management This research paves way development tailored strategies maximize benefits minimizing

Language: Английский

---

Medicinal Cannabis in the Management of Anxiety Disorders: A Systematic Review

Psychiatry Research, Journal Year: 2025, Volume and Issue: 350, P. 116552 - 116552

Published: May 17, 2025

Language: Английский

---

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients

International Clinical Psychopharmacology, Journal Year: 2024, Volume and Issue: 39(6), P. 350 - 360

Published: Feb. 1, 2024

This study aims to analyze changes in health-related quality of life (HRQoL) and safety patients with generalized anxiety disorder (GAD) prescribed a homogenous selection cannabis-based medicinal products (CBMPs). Patients Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes patient-reported outcome measures (PROMs) baseline up 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), EQ-5D-5L. Adverse events recorded using CTCAE version 4.0. A total 120 inclusion, which 38 (31.67%), 52 (43.33%), 30 (25.00%) oils, dried flower, both formulations CBMP. Associated improvements SQS, EQ-5D-5L at 1, 3, 6, months observed compared ( P < 0.010). There 24 (20.00%) who reported 442 (368.33%) adverse events, most mild (n = 184, 41.63%) moderate 197, 44.57%). reports an association between initiation homogeneous CBMP therapy severity HRQoL individuals GAD. Moreover, was well-tolerated follow-up. Further investigation through randomized controlled trials will ultimately be required determine causation.

Language: Английский

---

Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry

Journal of Pain & Palliative Care Pharmacotherapy, Journal Year: 2024, Volume and Issue: 38(2), P. 103 - 116

Published: April 2, 2024

Osteoarthritis accounts for 0.6% of disability-adjusted life years globally. There is a paucity research focused on cannabis-based medicinal products (CBMPs) osteoarthritic chronic pain management. This study aims to assess changes in validated patient-reported outcome measures (PROMs) and CBMP clinical safety patients with osteoarthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. Primary outcomes were Brief Pain Inventory (BPI), McGill Questionnaire (MPQ2), EQ-5D-5L, Generalized Anxiety Disorder-7 (GAD-7) questionnaire, Single-Item Sleep Quality Scale (SQS) at 1-, 3-, 6-, 12-month follow-ups baseline. Common Terminology Criteria Adverse Events v.4.0 used adverse event (AE) analysis. Statistical significance defined as p < 0.050. Seventy-seven met inclusion criteria. initiation correlated BPI severity (p = 0.004), interference 0.005), MPQ2 0.017) improvements all compared EQ-5D-5L index 0.026), SQS 0.001), GAD-7 0.038) up 6 3 months, respectively. Seventeen participants (22.08%) recorded 76 mild AEs (34.86%), 104 moderate (47.71%), 38 severe (17.43%). Though causality cannot be assumed this observational study, results support development randomized control trials osteoarthritis management CBMPs.

Language: Английский

---

An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry

Neuropsychopharmacology Reports, Journal Year: 2023, Volume and Issue: 43(4), P. 616 - 632

Published: Dec. 1, 2023

While there is increasing evidence of the effects cannabis-based medicinal products (CBMPs) on health-related quality life (HRQoL), a major limitation current literature heterogeneity studied CBMPs. This study aims to analyze changes in HRQoL patients prescribed homogenous selection CBMPs.Primary outcomes were patient-reported (PROMs) at 1, 3, 6, and 12 months from baseline. The secondary outcome was an adverse events analysis. Statistical significance defined as p < 0.050.1378 Adven® CBMPs (Curaleaf International, Guernsey, UK) included final 581 (42.16%) participants users cannabis 641 (46.51%), 235 (17.05%), 502 (36.43%) treated with oils, dried flowers, or combination two, respectively. Improvements found all PROMs each route administration baseline (p 0.010). Those flower only both oils experienced greater improvements GAD-7, SQS, EQ-5D-5L index values 0.050). There no difference between those > 3663 (265.82%) reported by 297 (21.55%) patients.There associated improvement self-reported anxiety, sleep quality, treatment formulations including most likely show clinical improvement. However, these results must be interpreted caution given limitations design.

Language: Английский

---

A Preliminary Study Looking at the Use of Mindful Compassion and Cannabis Suppositories for Anodyspareunia among Men Who Have Sex with Men (MSM)

Psychoactives, Journal Year: 2024, Volume and Issue: 3(3), P. 384 - 399

Published: Aug. 7, 2024

Research on the use of cannabis rectal suppositories for analgesia is limited. Few trials have evaluated combined mindfulness and anodyspareunia in men who sex with (MSM). This preliminary study, including a randomised control trial (RCT) content analysis, assessed effectiveness an online mindful-compassion suppository intervention among 52 British MSM (aged 18–50) predominantly identified as bottoms (recipients anal sex). Participants were randomly allocated to one four groups based whether they using suppositories: adjunct (CSMF), only (CS), mindful compassion (MF) care usual/control (CAU). Assessments measuring compassion, sexual functioning, self-efficacy, well-being, levels completed at weeks 0, 4, 12. Anodyspareunia lower CSMF group compared other (CS/MF/CAU), p = 0.031. Feedback revealed that participants felt potentiated effects during intimacy, reducing pain enhancing well-being. study warrants larger-scale investigation establish role anodyspareunia.

Language: Английский

---

Prescribed Medicinal Cannabis for the Treatment of Chronic Pain Comorbid with Depression: Real World Evidence from Project Twenty21

OBM Integrative and Complementary Medicine, Journal Year: 2024, Volume and Issue: 09(02), P. 1 - 18

Published: June 5, 2024

Chronic pain is one of the most common conditions for which people seek treatment with cannabis-based medicinal products (CBMPs) and there mounting real world evidence that CBMPs are safe effective in treating pain. Many chronic also experience major depression it unknown whether patients derive equal benefit from as those who not depressed since comorbidities usually an exclusion factor RCTs. This study aimed to investigate without co-morbid same improvement quality life outcomes after three months medical cannabis treatment. Data were derived Project Twenty21 (T21), largest observational studies UK. Baseline data available 1816 three-month follow-up 1058 these patients. Logistic regression models used examine relationship between comorbid controlling sociodemographic factors. Prescribed was associated marked reductions severity interference improvements aspects general health life. A substantial portion (23.4%) reported depression. Patients more at baseline (mean = 7.5 vs 6.8, p < 0.01) while no significant difference 5.9 6.0, > 0.05). Depression status did predict reduction months, scores, age number total predicted some outcomes. These results indicate should be a barrier accessing

Language: Английский

---